BEIJING – Antibody developer Akeso Biopharma Inc., from China's Guangdong province, closed a $150 million series D financing round to advance its pipeline, especially the two PD-1-based bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results